MARKET

IONS

IONS

Ionis Pharmaceuticals
NASDAQ
86.50
+3.02
+3.62%
After Hours: 86.50 0 0.00% 17:43 02/06 EST
OPEN
84.85
PREV CLOSE
83.48
HIGH
86.59
LOW
84.18
VOLUME
2.00M
TURNOVER
--
52 WEEK HIGH
86.74
52 WEEK LOW
23.95
MARKET CAP
14.01B
P/E (TTM)
-50.4726
1D
5D
1M
3M
1Y
5Y
1D
Expert Outlook: Ionis Pharmaceuticals Through The Eyes Of 6 Analysts
Benzinga · 18h ago
Ionis Pharmaceuticals Is Maintained at Overweight by Piper Sandler
Dow Jones · 23h ago
Ionis Pharmaceuticals Price Target Raised to $87.00/Share From $77.00 by Piper Sandler
Dow Jones · 23h ago
Piper Sandler Maintains Overweight on Ionis Pharmaceuticals, Raises Price Target to $87
Benzinga · 23h ago
Ionis Pharmaceuticals price target raised to $87 from $77 at Piper Sandler
TipRanks · 1d ago
IONIS PHARMACEUTICALS INC <IONS.O>: PIPER SANDLER RAISES TARGET PRICE TO $87 FROM $77
Reuters · 1d ago
Ionis Regulatory Wins Highlight Growing Rare Disease Revenue Potential
Simply Wall St · 1d ago
Top Ionis Pharma Executive Cashes In With Major Stock Move
TipRanks · 2d ago
More
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.

Webull offers Ionis Pharmaceuticals Inc stock information, including NASDAQ: IONS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IONS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IONS stock methods without spending real money on the virtual paper trading platform.